[Guidelines for the management of HCV infection in HIV-infected patients. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani].
It is crucial to ensure an optimal clinical management of HCV infection in HIV-co-infected persons. The reasons for the development of guidelines on HCV-infection treatment in HIV-infected persons arise from the need for a standardised management of HIV/HCV coinfection in our Institute. The aim of these guidelines are: to clarify principles of clinical management of HCV infection in HIV-infected patients to care-providers; to improve the awareness of HIV-infected patients cared for our Institute on current management of HCV infection; to improve the quality of care on this topic. These guidelines, based on Evidence based Medicine principles, have been developed by a panel of experts, who conducted a systematic review of the literature, mainly taking into account current international recommendations. In the present document, the most frequent clinical presentation occurring in the management of HIV/HCV co-infected patients at our Institution are discussed. The adherence to present guidelines and their effectiveness at our Institution, outcome indicators will be evaluated. The present guidelines cannot entirely substitute the judgement of an expert clinician. However, adherence to these guidelines will contribute to the improvement of the standard of care of HIV/HCV-co-infected persons.
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy.
G
G
Antonucci
A
A
Antinori
E
E
Boumis
P
P
De Longis
M
M
Gentile
E
E
Girardi
F N
FN
Lauria
P
P
Narciso
P
P
Noto
F
F
Palmieri
A
A
Oliva
N
N
Petrosillo
S
S
Rosati
R
R
Urso
G
G
Tocci
V
V
Tozzi
U
U
Visco Comandini
G
G
Ippolito
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015897:Comorbidity; D019468:Disease Management; D004347:Drug Interactions; D019317:Evidence-Based Medicine; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D010865:Pilot Projects; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D012367:RNA, Viral